Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.12 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.12 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, reflecting concerns about market conditions. They did not offer specific guidance or metrics for future performance.
Management did not provide specific insights into revenue performance.
The company acknowledged challenges in the current market environment.
The earnings report indicates that Arrowhead Pharmaceuticals is facing challenges, particularly reflected in the negative EPS. The stock dropped by 10.91%, likely due to investor concerns over the lack of revenue details and guidance. This reaction suggests uncertainty about the company's future performance and market position.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KRATOS DEFENSE & SEC
May 12, 2009